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ABSTRACT
Invasive nature and pain caused to patients inhibit the routine use of tissue biopsy-based procedures 
for cancer diagnosis and surveillance. The analysis of extracellular vesicles (EVs) from biofluids have 
recently gained significant traction in the liquid biopsy field. EVs offer an essential “snapshot” of their 
precursor cells in real time and contain information-rich collection of nucleic acids, proteins, lipids, etc. 
The analysis of protein phosphorylation, as a direct marker of cellular signaling and disease progression, 
could be an important stepstone to successful liquid biopsy applications. Here, we introduce a rapid EV 
isolation method based on chemical affinity called EVtrap (Extracellular Vesicles Total Recovery and 
Purification) for EV phosphoproteomics analysis of human plasma. Incorporating EVtrap with high 
performance mass spectrometry (MS), we were able to identify over 16,000 unique peptides representing 
2,238 unique EV proteins from just 5 μL plasma sample, including most known EV markers, with 
substantially higher recovery levels compared to ultracentrifugation. Most importantly, more than 5,500 
unique phosphopeptides representing almost 1,600 phosphoproteins in EVs were identified using only 1 
mL of plasma. Finally, we carried out quantitative EV phosphoproteomics analysis of plasma samples from 
patients diagnosed with chronic kidney disease or kidney cancer, identifying dozens of phosphoproteins 
capable of distinguishing disease states from healthy controls. The study demonstrates the potential 
feasibility of our robust analytical pipeline for cancer signaling monitoring by tracking plasma EV 
phosphorylation.
KEY WORDS
Extracellular vesicles, exosomes, proteomics, phosphoproteomics, EVtrap, kidney cancer, renal cell 
carcinoma, LC-MS.
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Currently the most widespread method for clinical cancer profiling and disease diagnosis involves 
a tumor biopsy, an invasive and painful procedure, and one that certainly is impractical for early-stage 
detection. As certain cancer becomes a more chronic disease that requires active monitoring over longer 
periods of time, tissue biopsies on a continuous basis are no longer a realistic scenario. As a result, “liquid 
biopsies” – analysis of biofluids such as plasma, serum, urine – have gained much attention as a potentially 
useful source of diagnostic biomarkers.1-4 Liquid biopsies offer numerous advantages for a clinical analysis, 
including non-invasive collection, suitable sample collection for longitudinal disease monitoring, better 
screenshot of tumor heterogeneity, higher stability and sample volumes, faster processing times, lower 
rejection rates and cost. However, there are technical challenges and shortcomings with the most common 
focus of liquid biopsy – circulating tumor cells (CTCs) and cell-free DNA (cfDNA) – including their 
heterogeneity, extreme rarity and high fragmentation levels.5-9 
In addition, current analyses overwhelmingly focus on genetic information – usually gene 
mutations. While genetic testing is valuable, it could greatly benefit from an additional layer of biological 
information. The ability to detect the genome output – active proteins – can provide useful real-time 
information about the organism’s physiological functions and disease progression, particularly in cancer.10-
13 Oncologists understand the value of protein testing and immunoassays and can easily interpret the results. 
Compared to gene panel testing, immunoassays, once developed, are relatively inexpensive and are easier 
to get adopted in clinical settings. 
To help overcome some of the challenges associated with the current liquid biopsy methods a new 
field has generated a lot of interest over the past few years – profiling of cell-secreted extracellular vesicles 
(EVs, which include microvesicles and exosomes).14, 15 EVs provide an effective and ubiquitous method 
for intercellular communication, stimulation of immune system, removal of harmful materials and serve 
many more functions.16-18 As these are shed into every biological fluid and embody a good representation 
of their parent cell, analysis of the EV cargo has great promise for biomarker discovery and disease 
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diagnosis.19, 20 Previous studies also revealed that EV-based disease markers could be identified before the 
onset of symptoms or physiological detection of a tumor, making them promising candidates for early-stage 
disease detection.21, 22 
Despite the significant recent excitement and efforts, a standardized method for collecting and 
processing EVs has not yet been developed.23 Differential centrifugation with ultracentrifugation (UC) as 
the final step is generally considered the “gold standard” for EV isolation (particularly for exosomes). 
However, this approach is highly time-consuming (typically 6-22 hours), requires dedicated equipment, 
and is low-throughput, thus not suitable in a clinical setting due to poor reproducibility.24-27 In addition, 
multiple studies have shown that the exosome recovery rate after ultracentrifugation is only 5-25%.27-29 
Several other groups have published and commercialized new methods for EV isolation, which include 
polymer-induced precipitation,30, 31 antibody-based capture,32, 33 affinity filtration,34 size-exclusion 
chromatography,29, 35 etc. However, each one has its own limitations, including low recovery rate (usually 
similar or slightly worse than ultracentrifugation) and high contamination levels,25-27, 29, 34, 36-40 While these 
can certainly be used as a faster alternative to UC, at 5-25% published yields, their efficiency of isolation 
still leaves much room for improvement. As result, there is a critical need for a fast, reproducible and 
inexpensive approach for EV isolation that would allow a much more complete capture and extraction of 
pure EVs for research and clinical purpose. This prerequisite is particularly essential for the analysis of 
active and tumor-specific proteins and phosphoproteins.
We have recently introduced a novel magnetic bead approach based on chemical affinity for urinary 
EV capture and purification.41 The technology, named EVtrap (Extracellular Vesicles total recovery and 
purification), enables complete capture of EVs onto beads modified with a combination of hydrophilic and 
aromatic lipophilic groups that have high affinity toward lipid-coated EVs. These modified amphiphilic 
beads are capable of capturing EVs with high purity, and we found that the method enables >95% recovery 
yield of all EVs present in the urine sample, a significant improvement compared to ultracentrifugation and 
commercial exosome isolation methods. We applied LC-MS analyses on proteins from EVs isolated by 
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EVtrap, and all known detectable exosome markers were significantly enriched after EVtrap compared to 
UC. We also identified the largest number of phosphoproteins present in urinary EVs (>1,000 
phosphoproteins in 10 mL of urine). 
While the EVtrap approach showed a dramatic improvement in urinary EV analysis, blood is a 
much more complex milieu with many more challenges in sample preparation and analysis. The scale of 
free proteins and other molecules present in plasma or serum that affect EV analysis is orders of magnitude 
higher than in urine. Nonetheless, blood contacts with most cells and organs, and is considered as the most 
important biofluid for liquid biopsy. A majority of EVs from different types of cells are likely secreted into 
the blood. Therefore, in order to enable blood-based liquid biopsy for disease diagnosis, in this study we 
attempted to achieve EV isolation from plasma based on the EVtrap approach, with specific focus on EV 
phosphoproteomics. We carried out a comparison between EVtrap, ultracentrifugation and other commonly 
used exosome isolation methods. Using Western Blotting, silver staining and LC-MS analyses, we found 
that EVtrap captured EV markers from plasma at significantly higher levels and improved EV capture purity 
compared to UC and other standard EV isolation techniques. 
We further utilized the EVtrap approach for EV phosphoproteome analysis from plasma. Protein 
phosphorylation is a key control mechanism for cellular regulatory pathways, and one often targeted by 
drug developers to create inhibitors that block signaling pathways involved in cancer and other diseases. 
However, as far as liquid biopsy is concerned, phosphoproteins have been virtually ignored due to their 
perceived instability and low abundance level in biofluids until our recent study.42 Phosphoproteins are 
typically present at sub-stoichiometric levels, and thus the recovery rate during sample preparation steps 
must be efficient in order to achieve their detection. To carry out EV plasma phosphoproteome analysis, 
we utilized the EVtrap approach to capture EVs from 1 mL plasma sample and compared this method to 
standard ultracentrifugation. We demonstrated efficient analysis of plasma phosphoproteome with the 
EVtrap isolation method, and its feasible application for disease diagnosis. 
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Finally, we utilized our EVtrap-LCMS approach to examine EV proteome and phosphoproteome 
differences between healthy plasma controls and plasma samples from patients with chronic kidney disease 
and kidney cancer. These efforts resulted in discovery of several highly promising potential biomarkers for 
non-invasive detection of renal cell carcinoma from plasma, which we will further validate in upcoming 
studies.
EXPERIMENTAL SECTION
Experimental details on materials, ultracentrifugation, EV isolation by other methods, Western 
Blotting, silver staining, LC-MS analysis and data processing are included in the supporting information.
Sample collection
Plasma samples were collected under approval from Purdue University Human Research Protection 
Program and Indiana University Human Subjects Office Institutional Review Boards, and all patients were 
properly consented before samples were collected. All frozen samples were thawed and centrifuged 2,500 
× g for 10 min to remove platelets, apoptotic bodies and other large particles and aggregates.
For EVtrap characterization experiments, we used plasma from healthy individuals. For the kidney 
cancer analysis part of the project, we used 1 mL each of plasma from: a) 5 healthy individuals (no known 
kidney-related disease); b) 5 patients with diagnosed chronic kidney disease (CKD), some of whom were 
also diagnosed with kidney stones; and c) 5 patients diagnosed with the most common form of kidney 
cancer - renal cell carcinoma (RCC).
Extracellular Vesicle Isolation by EVtrap 
EVtrap beads were provided by Tymora Analytical as a suspension in water, and were used as described in 
more detail before.41 The plasma samples were diluted 20-fold in the diluent buffer and the EVtrap beads 
were added to the samples at 1:2 v/v ratio, and the samples incubated by end-over-end rotation for 30 min, 
according to manufacturer’s instructions. After supernatant removal using a magnetic separator rack, the 
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beads were washed with PBS and the EVs eluted by a 10-min incubation with 200 mM triethylamine (TEA, 
Millipore-Sigma). The samples were fully dried in a vacuum centrifuge.
LC-MS Sample Preparation
The isolated and dried EV samples were lysed to extract proteins using the phase-transfer surfactant 
(PTS) aided procedure.43 First, EVs were solubilized in the lysis solution containing 12 mM sodium 
deoxycholate, 12 mM sodium lauroyl sarcosinate, 10 mM TCEP, 40 mM CAA, and phosphatase inhibitor 
cocktail (Millipore-Sigma) in 50 mM Tris·HCl, pH 8.5 by incubating 10 min at 95°C. This step also 
denatured, reduced and alkylated the proteins. The samples were diluted fivefold with 50 mM 
triethylammonium bicarbonate and digested with Lys-C (Wako) at 1:100 (wt/wt) enzyme-to-protein ratio 
for 3 h at 37°C. Trypsin was added to a final 1:50 (wt/wt) enzyme-to-protein ratio for overnight digestion 
at 37°C. The samples were acidified with trifluoroacetic acid (TFA) to a final concentration of 1% TFA. 
Ethyl acetate solution was added at 1:1 ratio to the samples. The mixture was vortexed for 2 min and then 
centrifuged at 20,000 × g for 2 min to obtain aqueous and organic phases. The organic phase (top layer) 
was removed, and the aqueous phase was collected, dried down to <10% original volume in a vacuum 
centrifuge, and desalted using Top-Tip C18 tips (Glygen) according to manufacturer’s instructions. Each 
sample was split into 99% and 1% aliquots for phosphoproteomic and proteomic experiments respectively. 
The samples were dried completely in a vacuum centrifuge and stored at -80°C. For phosphoproteome 
analysis, the 99% portion of each sample was subjected to phosphopeptide enrichment using PolyMAC 
Phosphopeptide Enrichment kit (Tymora Analytical) according to manufacturer’s instructions, and the 
eluted phosphopeptides dried completely in a vacuum centrifuge. For phosphoproteomics analysis the 
whole enriched sample was used, while for proteomics only 50% of the sample was loaded onto LC-MS.
Data Availability 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE44 partner repository with the dataset identifier PXD017994.
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Isolation of plasma EVs by EVtrap
Here, we adapted the EVtrap approach for purification of EVs from plasma samples. The collected 
and frozen plasma samples were thawed, and platelets and other large particles removed by centrifugation 
at 2,500 × g for 10 minutes. The pre-cleared plasma samples were diluted 20-fold in PBS and incubated 
with EVtrap beads for 30 min.41 The captured EVs were eluted with 10-min incubation in 200mM 
triethylamine and the resulting EV samples dried in a vacuum centrifuge. Transmission Electron 
Microscopy (TEM) analysis showed the standard cup-shaped exosomes/microvesicles recovered (Figure 
1A,B). Examination of the post-EVtrap eluted extracellular vesicles by Nanoparticle Tracking Analysis 
(NTA) and Tunable Resistive Pulse Sensing (TRPS) both demonstrated a similar range of the isolated EVs, 
with majority being in the 100-200 nm range (Figure 1C,D). The mode particle diameter was 137 nm and 
134 nm, while d50 was 154 nm and 143 nm for NTA and TRPS respectively. While both methods showed 
pretty similar data, we found that TRPS produced more consistent and accurate results due to their 
nanopore-based single-particle analysis capabilities.
For the initial recovery yield comparison and method validation, we used 100K × g 
ultracentrifugation “gold standard” as the control method (with and without PBS wash). 
An equivalent of 5 µL plasma of the EV pellet from this ultracentrifugation (labeled as 100K UC) was 
loaded on the gel for Western Blot analysis. The supernatant after 100K UC was also further incubated with 
EVtrap beads to check if any residual exosome population was left in the supernatant after UC. Likewise, 
5 µL of direct plasma was used to capture EVs by EVtrap. After 30-min incubation the beads were washed 
and EVs were eluted and dried. Then the internal cargo was extracted by boiling in the LDS sample buffer 
(lithium dodecyl sulfate) and loaded on the gel. All samples were loaded on the same gel and detected by 
Western Blotting using a primary antibody against CD9 (a common exosome marker). The experiment was 
carried out 3 separate times for quantitation, with each isolation using a plasma from the same source (the 
complete blots for all three experiments are available in Supplementary Figure S1). A representative 
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Western Blot is shown in Figure 2A, and the quantitative values for each CD9 band signal are listed in the 
bar graph in Figure 2B. For comparison, we also loaded 0.05 µL of plasma (~4 µg protein; 1% of the 
amount used by other methods), which, as expected, was too low to produce any detectable CD9 signal. As 
the results show, ultracentrifugation step indeed captured only a portion of the exosomes (some were likely 
lost during 10,000 × g pre-treatment), with EVtrap being able to isolate and produce >7-fold more CD9 
signal. If EVtrap method is considered as capturing the majority of exosomes, then UC can be calculated 
to capture ~14% of EVs on average - a recovery rate similar to other studies,27, 28 and equivalent to what we 
found for urine EVs. Detection of EVs by EVtrap from the UC supernatant further confirmed the incomplete 
isolation by UC, showing a large percentage of EVs remaining in the supernatant (Figure 2). We would 
like to note that the high-yield capture by EVtrap was achieved after only a 45-min procedure, in 
comparison to >5 hrs needed for the UC protocol. 
Besides ultracentrifugation, we also sought to compare EVtrap method to other common EV 
isolation approaches. We tested three common EV isolation kits – based on membrane affinity spin 
method,34 size-based filtration tube, and polymer-based exosome precipitation kit.30 100 µL of plasma was 
used in each case and 5 µL equivalent was loaded on the same gel as the previous samples. As the results 
in Figure 2 demonstrate, the alternative methods produced somewhat similar or better exosome recovery 
signal compared to 100K ultracentrifugation, matching the previously published results for these 
methods.27, 29, 34, 37, 38 However, the low purity of these methods is a known disadvantage (as will also be 
shown further in this study). Therefore, it is difficult to implement them for subsequent protein analysis due 
to significant contamination from free plasma proteins. Nonetheless, EVtrap still produced the highest 
exosome recovery yield compared to any other approach (Figure 2A,B). All CD9 band signals from the 3 
replicate blots were quantified and mean signal intensities plotted on the bar graph in Figure 2B to show a 
better comparison between the methods. The stadard deviation error bars among EVtrap experiments are 
higher than we expected, but this is likely because the 3 replicates were carried out on separate gels and the 
Western Blotting analyses were also performed on separate membranes. 
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Our overall goal was to show how much of the EV amount can be obtained from the same volume 
of plasma. In many cases, the volume of clinical samples is very limited, and therefore the ability to enrich 
a high amount of EVs from a small volume would be very advantageous. This is the reason we compared 
the EV recovery in each method using the same starting volume. Nonetheless, it is common to assess the 
EV marker signal in relation to total protein amount. We carried out an additional experiment of CD9 
Western Blot comparing the signal after EVtrap enrichment and 100K ultracentrifugation. Here, the 
recovered EVs were resuspended, lysed, and the concertation of each sample determined by Nanodrop. 
Then 5 µg of each protein amount was loaded on a gel and analyzed with anti-CD9 antibody. As the data 
in the Supplementary Figure S2 demonstrate, EVtrap again demonstrated a significant increase in CD9 
signal when the loading sample amount was normalized by concentration.
Assessment of plasma EV purity 
Besides EV capture yield analysis, another important feature is the purity of the isolated EVs. This 
is particularly important for plasma samples because the free proteins in plasma are present at 70-80 mg/mL, 
levels that can significantly impede biomarker analysis. To examine the amount of contamination by free 
plasma proteins present after each EV capture method, we used 5 µL of plasma for each experimental 
treatment and detected the resulting EV sample with silver staining for total protein analysis. The samples 
were processed in the manner identical to those in the previous EV recovery experiments and loaded on the 
gel in the same sequence. As expected, 100K UC sample had lower level of contamination when compared 
to 0.05 µL (1%) of direct plasma loaded, and much less after the PBS wash (Figure 3A). Three commercial 
kits tested (same as used in the first experiment) resulted in very high amount of contamination, and 
therefore low purity of EV isolation. When compared to 1% plasma sample loaded, all three commercial 
methods had >1% free protein contaminants remaining. As a result, these methods would be very difficult 
to use for downstream proteome and phosphoproteome analyses. Perhaps this is the primary reason why 
most researchers use them for DNA/RNA detection only. By comparison, EVtrap isolation showed the 
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cleanest sample compared to all three commercial products, and similar in contamination level compared 
to ultracentrifugation.
Examination of EVtrap reproducibility 
In order to analyze clinical samples in high-throughput manner, a method must be able to 
demonstrate low experimental variability. Thus, we also tested EVtrap sample-to-sample reproducibility. 
The EVtrap reproducibility experiments were carried out using nine 10 µL aliquots of plasma and the 
captured EV samples were then analyzed on the same blot using CD9 marker detection. The results shown 
in Figure 3B demonstrate outstanding sample-to-sample reproducibility with 3.2% coefficient of variation 
(CV). The expanded blot and the quantitative CD9 band values are shown in the Supplementary Figure 
S3.
LC-MS analysis of plasma EV proteome and phosphoproteome 
For our preliminary phosphoproteome analyses, we used 1 mL of plasma for EVtrap capture and 
for ultracentrifugation as the control (100K UC; carried out after the 10,000 × g centrifugation step). Our 
100K ultracentrifugation method (total UC time ~5 hours, including 1 wash step) produced 321 unique 
phosphopeptides from 177 unique phosphoproteins (Supplementary Table S1). However, when EVtrap 
was used for 30-min capture, we saw a significant increase in phosphoproteome identification levels. We 
identified 5,570 unique phosphopeptides from 1,593 unique phosphoproteins using only 1 mL of plasma 
and a single 60-min LC-MS run (Supplementary Table S2). This confirms that most phosphoproteins 
were simply not detectable by MS after ultracentrifugation.
To complement our phosphoproteome data, we also carried out direct proteomics analysis from 
plasma EVs. For these samples, only 5 µL equivalent of plasma was used. 100K UC procedure produced 
3,282 peptides and 406 total proteins (Supplementary Table S3). EVtrap capture approach on the other 
hand allowed identification of 16,266 peptides from 2,238 unique proteins (Supplementary Table S4).
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We further carried out label-free quantitation of EV proteins isolated by EVtrap and by UC. Figure 
4 shows the total signal increase of the identified proteins and phosphoproteins compared to UC 
(Supplementary Table S5 and S6). In our experiment, we have identified 88 out of 100 common EV 
markers and proteins published in ExoCarta45-47 (marked EV protein data in Supplementary Table S7). 
Overall, the average signal increase in EV markers and total EV proteome level is 78-fold and 69-fold, 
respectively, for EVtrap compared to UC. This is noteworthy because many other studies have shown that 
different methods enrich different exosome populations with various success rates,38, 48 With EVtrap, it 
appears that the complete EV profile is recovered. Markedly, the overall increase in the phosphoproteome 
signal is ~85-fold. The significant increase in the phosphoproteome signal is due to most of the 
phosphopeptides being undetectable by LC-MS after ultracentrifugation, thus resulting in the relative 
abundance ratio of 100 (maximum set fold-change in Proteome Discoverer). This difference in intensities 
is substantial. While the internal RNA/DNA molecules and many proteins can still be detected even after 
low EV recovery, phosphoproteins are already present at very low concentrations. After poor sample 
preparation they would be essentially undetectable on a discovery instrument like mass spectrometer. These 
data confirmed our hypothesis that in order to achieve efficient identification and quantification of 
phosphoproteome in EVs, a method like EVtrap is necessary to enable simple and highly efficient EV 
isolation and recovery. 
Finally, for purity comparison purpose, we also quantified the signal of serum albumin and other 
common high-abundant plasma proteins. The quantitative LC-MS data showed a similar intensity (ratio of 
1.05) of serum albumin in the EV sample isolated by EVtrap compared to UC (Figure 4). When analyzing 
other high-abundant plasma proteins, the average increase in signal in the EVtrap sample was 1.48-fold 
(marked plasma protein data in Supplementary Table S7). While there is a small increase in contaminants 
level of about 1.48-fold after EVtrap capture, this increase is not significant compared to the 78-fold 
increase in EV markers and 69-fold increase in total EV protein amount. Therefore, it is apparent from 
these results that EVtrap indeed significantly improves protein and phosphoprotein detection from plasma 
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EVs without significantly increasing the level of contamination compared to the standard isolation methods 
like UC.
The data demonstrate that EVtrap can be applied to directly process plasma in only 30 minutes, 
which would be highly useful for routine clinical analysis. With 1 mL plasma being sufficient to identify 
over a thousand of phosphoproteins, and 5 µL plasma enough to identify over two thousand unique proteins, 
the volume is also convenient for routine analysis.
EVtrap-based plasma EV phosphoproteome analysis of kidney cancer and CKD patient samples
Protein phosphorylation is a determining regulatory mechanism for pathological pathways directly 
linked to cancer and other diseases. With one previous study from our group unveiling the possibility of 
using plasma EV phosphoproteins as candidate biomarkers for breast cancer,42 we believe our novel 
benchmarked EVtrap technique allows a more efficient and robust way for phosphoprotein biomarker 
discovery using plasma EVs. Here, we focused on diseases related to kidney, including kidney cancer 
(specifically, renal cell carcinoma, RCC), which accounts for ~3% of human malignancies.49 The currently 
most common methods of diagnosis include computerized tomography (CT) or computerized axial 
tomography (CAT) scan followed by invasive tumor biopsy, which are far from optimal.50, 51 In this study, 
we carried out preliminary efforts to detect potential biomarkers of kidney cancer using plasma EV samples 
to enable non-invasive diagnosis. The general workflow for the whole process of plasma EV proteome and 
phosphoproteome analysis is illustrated in Figure 5. In order to distinguish kidney cancer accurately from 
non-cancerous conditions, chronic kidney disease (CKD) patients plasma samples were included as an 
additional control in our study.52
EVs were isolated from human plasma samples (n = 5 biological replicates/group × 3 groups = 15), 
as described in Figure 5 using our EVtrap approach. EV proteins were extracted and digested by trypsin 
with the aid of phase-transfer surfactants.43 After detergent removal and desalting, 1.5% (~1ug) of each 
peptide sample was stored for direct proteome analysis. The remainder of each peptide sample was used 
for phosphopeptide enrichment with in-house developed PolyMAC dendrimer-based phosphopeptide 
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enrichment method53 prior to LC-MS analysis. Both proteome and phosphoproteome fractions were 
analyzed on a Ultimate 3000 nanoLC coupled with Q Exactive HF-X mass spectrometer.54 Additionally, 
indexed Retention Time Standard containing 11 artificial synthetic peptides was spiked into each sample 
and utilized as an internal standard to reduce run-to-run variations and assist with peptide quantitation.55
This streamlined procedure resulted in identification of 146 significantly changing phosphoproteins 
and 28 significantly changing proteins in kidney cancer samples compared to control. Likewise, we 
identified 156 significantly changing phosphoproteins and 16 significantly changing proteins in CKD 
samples compared to control. Comparison between the RCC and CKD samples revealed 44 
phosphoproteins and 10 proteins that are significantly different between these two groups. Overall 
quantitative proteomics and phosphoproteomics data are available in Supplementary Tables S8 and S9. 
Further, in-depth data analysis was employed to obtain statistical results and generate visualized 
hierarchical clustering groups (heatmaps) and volcano plots (Figure 6). The proteins and phosphoproteins 
included in the two heatmaps (6A and 6B) are listed in the Supplementary Table S10.
Hierarchical clustering analyses on quantitative proteomics and phosphoproteomics were 
performed on all individual biological replicates with the threshold of p-value at 0.05. Clusters of proteins 
or phosphoproteins with consistent significantly changing abundance levels among categories were 
highlighted and annotated on the right. For a more global visualization of the quantitation results, the 
volcano plots with basis of t test statistics featured the quantitative comparison analyses of the plasma EV 
proteomes (top) and phosphoproteomes (bottom) between every two sample categories out of three. 
Proteins and phosphoproteins with considerable up- and down-regulation in diseases were exposed through 
a t-test permutation-based FDR (FDR = 0.05, the horizontal dash line at -log(p-value) = 1.30) and a 
difference on fold-change (fold-change = 2, the vertical dashed line at log2(ratio) = ±1), with all five 
biological replicates in each group being counted. Notably, a greater number of phosphoproteins were 
upregulated in disease states compared to control samples, a promising outcome for further clinical 
validation.
We focused on several significantly changing proteins and phosphoproteins and identified four 
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most promising biomarker representatives, with their relative abundances in three categories from DDA-
mode quantitation sketched in linear box-and-whiskers plots (Figure 7). Indeed, prior studies substantiated 
the scientific rationale of these targets to be possible disease biomarkers. The anchoring function of 
cardiomyopathy-associated protein 5 (CMYA5) is corroborated to mediate the subcellular 
compartmentation of protein kinase A (PKA) by binding to PRKAR2A implicated in the STRING network 
analysis,56, 57 although no straightforward evidence yet exists underlining its cancer-correlated mechanism 
behind the abundance elevation (Figure 7A). Likewise, referring to KEGG database, the enhanced signal 
of Crk-like protein (CRKL) in phosphorylated form was supported by its critical role in PI3K-Akt signaling 
pathway in cancer formation (Figure 7B).58, 59 With regard to phosphoprotein LYRIC (MTDH) as a 
potential marker, it appears promising due to its interaction with the AKT1 and HRAS, both of which serve 
as key components in kidney carcinoma pathway. Moreover, the networks between MTDH and MMP9, 
MYC and ZBTB16 are also essential players in cancer progression (Figure 7C).59 Beyond cancer-relevant 
roles, a previous finding of apolipoprotein A-IV (APOA4) as a concentration-increased protein in chronic 
renal disease underlines its feasibility as a kidney stone/inflammation-specific protein, which was mainly 
attributed to kidney metabolism (Figure 7D).60 Additional linear box-and-whiskers plots for other potential 
candidates are shown in Supplementary Figures S4-S6.
DISCUSSION
Along with emerging research in EVs and exosomes, total EV and/or exosome capture and 
purification has been the focus of many recent studies that attempt to develop a simple and efficient EV 
isolation protocol. Here, we present a novel chemical affinity-based capture method for effective EV 
isolation from plasma. The EVtrap method enables the capture of complete EV profile based on the lipid 
bilayer structure of these vesicles and the unique combination of the hydrophilic and aromatic lipophilic 
groups on the synthesized beads. The binding of these combinatorial amphiphilic groups appears to be in 
part through the shift from hydrophilicity to amphiphilicity of these groups, electrostatic interactions and 
lipid affinity, and thus the EVs can be released with the increase in pH using TEA. The specificity of the 
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binding to the lipid bilayer membrane of EVs as opposed to free lipids and lipoproteins, as well as their 
aggregates, is further enhanced by the additives in the diluent buffer. 
We were able to isolate hundreds of phosphoproteins directly from plasma, and revealed its future 
applications in the clinical settings. While our previous publication on plasma EV phosphoproteome 
analysis produced strong data and demonstrated outstanding potential of this field,42 the EVtrap approach 
would be more suitable for routine EV analysis and biomarker discovery from clinically-relevant samples. 
The initial demonstration of this was implemented in this study of kidney cancer plasma EV 
phosphoproteomics. We strongly believe that the future of disease detection will depend on robust and 
reproducible analysis of low-abundant signaling proteins and phosphoproteins, especially for early cancer 
diagnosis and monitoring. It will supplement the current assays and offer an additional layer of important 
information not typically available from genetic tests.
Multiple studies have shown that there is a notable discordance between genomic information and 
actual proteome/phosphoproteome profile, with phosphoprotein information being much more relevant for 
cancer detection and molecular subtyping.10-12, 61, 62 A recent study published on breast cancer profiling 
indicated the utility of phosphoproteomic data to help clarify the highly complex genomic features.63 For 
example, genomic data have not been successful in treatment decisions with MTOR and PI3K inhibitors 
due to a myriad of mutations in multiple pathways, most not actionable.64 Here, the researchers were able 
to more confidently predict the drug response based on the phosphorylation of downstream signaling 
targets. In another example, close to half of HER2-positive breast cancer patients do not respond well to 
Herceptin.65 Likewise, a significant number of HER2-negative women do respond to Herceptin.66 In both 
cases downstream phosphorylation analysis can predict these response differences. These examples 
demonstrated the need to examine the more complete signaling pathways for better cancer subtyping in 
addition to the presence of mutations or a receptor. Being able to do this in a less invasive manner using 
plasma EV analysis would have an enormous public health benefit. Therefore, successful development of 
methods like EVtrap will be a substantial step forward in this objective.
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We have carried out a comprehensive assessment and comparison of the EVtrap method against 
several EV isolation methods for plasma proteome and phosphoproteome studies. The EVtrap method 
enables high recovery levels of exosomes with low contamination level and <5% CV. All detectable 
exosome markers were captured at higher levels than by the common ultracentrifugation approach. While 
most data in this study were generated using Western Blotting and LC-MS, the EVtrap-isolated vesicles 
can be used for different types of follow-up analyses. We expect that the captured EV cargo can also be 
processed for DNA/RNA examination. Because the proposed approach is magnetic beads based, it can be 
easily automated for a high-throughput screening or diagnostics assay in a hands-off manner. Researchers 
equipped with EVtrap will be able to uncover more low-abundant plasma biomarkers, such as those with 
post-translational modifications (PTMs). We hypothesize that low-abundant plasma EV proteins and 
phosphoproteins can one day be used for early-stage disease detection, longitudinal monitoring, and as 
companion diagnostics for targeted cancer treatments, particularly those involving kinase inhibitors. 
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Figure 1. Transmission electron microscopy (TEM) images of A) single EV, and B) multiple EVs 
captured from the plasma by EVtrap. TEM imaging of EVs was carried out on a HITACHI H-8100 
electron microscope (Hitachi, Tokyo, Japan) with an accelerating applied potential of 200 kV. C) 
Nanoparticle analysis using NTA after elution off EVtrap beads. D) Nanoparticle analysis using TRPS 
after elution off EVtrap beads.
100 nm 100 nm
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Figure 2. Comparison between ultracentrifugation (UC), EVtrap and 3 commercial methods for 
exosome capture. A) Detection of CD9 exosome marker using Western Blot. The lanes were loaded as 
follows: 0.05 µL plasma loaded directly, EVs isolated from plasma by UC with no additional wash 
steps, EVs isolated from plasma by UC with 1 wash step, EVs captured by EVtrap from the UC 
supernatant sample (leftover after UC), EVs captured by EVtrap from plasma directly, EVs captured 
from plasma by membrane filtration method, EVs captured from plasma by size exclusion method, EVs 
captured from plasma by polymer precipitation method. All loaded EV samples were from 5 µL plasma. 
B) Quantitation of WB data in (A) (n = 3).
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Figure 3. A) Silver stain total protein detection to access plasma protein contamination. Comparison 
between ultracentrifugation (UC), EVtrap and 3 commercial methods for exosome capture. The lanes 
were loaded as follows: 0.05 µL plasma loaded directly, EVs isolated from plasma by UC with no 
additional wash steps, EVs isolated from plasma by UC with 1 wash step, EVs captured by EVtrap 
from the UC supernatant sample (leftover after UC), EVs captured by EVtrap from plasma directly, 
EVs captured from plasma by membrane filtration method, EVs captured from plasma by size exclusion 
method, EVs captured from plasma by polymer precipitation method. All loaded EV samples were 
from 5 µL plasma. B) Test of EVtrap procedure reproducibility carried using 9 separate plasma samples 
from the same source – detection of CD9 signal.
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Figure 4. LC-MS proteome and phosphoproteome analyses of 100K UC and EVtrap samples. Fold change 
in overall signal between 100K UC and EVtrap experiments was quantified and plotted in a bar graph for: 
88 identified common exosome markers, all proteins identified (excluding known contaminants), all 
phosphoproteins identified, serum albumin, and other high-abundant free plasma proteins (usually treated 
as contaminants).
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Figure 5. Workflow of EV proteomics and phosphoproteomics analyses of plasma samples from healthy 
controls, patients diagnosed with CKD and kidney cancer.
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Figure 6. Hierarchical clustering analyses on quantitative proteomics (A) and phosphoproteomics (B) data. 
The gene names included in the two heatmaps (A) and (B) are listed in the Supplementary Table S10. C-
H) The volcano plots representing the quantitative comparison of the plasma EV proteomes (top) and 
phosphoproteomes (bottom). Top: C) CKD vs. healthy control in full proteome; D) kidney cancer vs. 
healthy control in full proteome; E) kidney cancer vs. CKD in full proteome. Bottom: F) CKD vs. healthy 
control in phosphoproteome; G) kidney cancer vs. healthy control in phosphoproteome; H) kidney cancer 
vs. CKD in phosphoproteome.
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Figure 7. Relative abundance data of the selected four proteins and phosphoproteins as potential markers 
to differentiate the relevant categories. All four targets demonstrate significant upregulation (P < 0.05) in 
patients diagnosed with kidney cancer or CKD compared to the other two categories. A) kidney cancer-
specific protein marker; B-C) kidney cancer-specific phosphoprotein markers; D) CKD-specific protein 
marker. All values are log2 conversions of protein or phosphosite normalized abundance levels as 
determined by LC-MS.
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